Modulation of capecitabine administration to improve continuity of adjuvant chemotherapy for patients with colorectal cancer: A phase II study.

In conclusion, the present study demonstrated good feasibility with retained quality of life and acceptable adverse effects (mostly low-grade), and the 5-days-on/2-days-off regimen should be further evaluated in future randomized controlled trials. The present study was registered in the University Hospital Medical Information Network (UMIN) clinical trial registry (no. UMIN000012813).
PMID: 31929883 [PubMed]

Source: Clinical Colorectal Cancer - January 15, 2020 Category: Cancer & Oncology Authors: Mizumoto Y, Yokoyama S, Matsuda K, Iwamoto H, Mitani Y, Tamura K, Nakamura Y, Murakami D, Oka M, Kobayashi Y, Yamaue H Tags: Mol Clin Oncol Source Type: research